MANCHESTER, NH--(Marketwired - Nov 17, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University's Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown®. This is the first study to evaluate sugardown®'s effectiveness with sugary beverages.
The single-center, randomized, controlled, crossover study is being conducted at SUGiRS. A total of 10 healthy, overweight adults are being enrolled in the study. The subjects will be administered three test portions: a serving of Sprite® soft drink containing 50 grams of carbohydrate; an equal portion of Sprite® with two sugardown® tablets; and an equal portion of Sprite® with four sugardown® tablets. Blood samples will be collected at regular intervals both before and after first ingestion of the soft drink. Each subject will complete a total of six test sessions over four weeks. The primary outcomes of the trial are postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
sugardown® is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown® is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy. In a previous study, sugardown® demonstrated up to a 60 percent reduction of glucose and insulin AUC when taken with rice, a food with a 100 percent glycemic index. Sugary soft drinks that also have high glycemic index, include disaccharides such as sucrose and maltose.
According to the U.S. Centers for Disease Control and Prevention (CDC), one-half of the U.S. population consumes sugar drinks on any given day, and 25 percent consumes at least 200 kcal (more than one 12-oz can of cola). The CDC reports that sugar drinks have been linked to poor diet quality, weight gain, obesity, and, in adults, Type 2 diabetes.
David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "Following our successful study of the effect of sugardown® in conjunction with solid food, we are eager to determine its effects when ingested with sugary drinks. The results will give us a more complete understanding of sugardown®'s potential benefits as a dietary supplement."
About SugarDown Co Ltd
SugarDown Co Ltd (Hong Kong) an affiliate of Advance Pharmaceuticals Company (APC), organized under the laws of Hong Kong. We have entered into an agreement with APC to develop markets for sugardown® in Hong Kong, China and Macau in addition to 12 other countries in Asia.
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also developed and markets sugardown®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.
Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
© Boston Therapeutics, Inc. All rights reserved.